• anticancer
• bioconjugates
• cancer cells
• metallodrugs
• MW-SPPS
• peptides
• platinum
• selectivity
• side effects
• targeting

The drug targeting and delivery (DTD) strategy relies on the use of suitable ligands or molecules capable of recognizing overexpressed biomarkers on the surface of cancer cells, thereby enhancing drug selectivity and reducing side effects. Through this approach, once bound to the biomarkers, the drugs are internalized and subsequently released into the cytoplasm. Among the most widely studied and used vectors for DTD, peptides undoubtedly hold a prominent position. This versatile and powerful technique also enables to overcome the poor cell permeability, a significant obstacle that has, historically, hindered the therapeutic application of metallodrugs. New Pt(II) complexes have been synthesized, characterized and linked to specific peptide sequences in order to evaluate the bioconjugates as targeted antitumor agents. The peptides were obtained through the solid-phase microwave-assisted synthesis (MW-SPPS) and characterized by MS analysis. These studies were conducted at the BIOCIS Laboratory of CY Cergy University, in Paris. The characterization of the metallic complexes was conducted using ¹H-NMR, ¹³C-NMR spectroscopy and elemental analysis. Coupling attempts were conducted in both solid-phase and solution.